Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.3976 +0.0198 (+5.24%)
Streaming Delayed Price Updated: 10:45 AM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
7 Cheap Biotech Stocks to Buy Now
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
Via Benzinga
Analyst Ratings for bluebird bio
Over the past 3 months, 6 analysts have published their opinion on bluebird bio (NASDAQ:BLUE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
Via InvestorPlace
Expert Ratings For bluebird bio
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: 
Via Benzinga
Bluebird Bio Joins Layoff Band Wagon As Gene Therapy Biotech Cuts Staff To Reduce Costs
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the... 
Via Benzinga
55 Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company. 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US
From bluebird bio, Inc.
Via Business Wire
FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials
The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products. 
Via Benzinga
bluebird bio's Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, bluebird bio (NASDAQ:BLUE) posted sales of $1.61 million. Earnings were up 28.49%, but bluebird bio still reported an overall loss of $... 
Via Benzinga
76 Biggest Movers From Yesterday
Gainers Houston American Energy Corp. (NYSE: HUSA) surged 494.7% to close at $11.30 on Monday amid continued momentum and an increase in the price of oil. Imperial Petroleum Inc... 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Niu Technologies Shares Plunge
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 600 points on Monday. The Secretary of State Antony Blinken said on Sunday that the... 
Via Benzinga
Expert Ratings For bluebird bio
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Mid-Day Market Update: Nasdaq Drops 250 Points; Bed Bath & Beyond Shares Surge
U.S. stocks traded lower midway through trading, with the Nasdaq dropping 250 points on Monday. The Secretary of State Antony Blinken said on Sunday that the United States and its... 
Via Benzinga
Why Bluebird Bio Shares Are Tumbling Today
Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ: BLUE) ended 2021 with a cash and equivalents balance of approximately $442 million.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022
Upgrades According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics... 
Via Benzinga
46 Stocks Moving In Monday's Mid-Day Session
Gainers Houston American Energy Corp. (NYSE: HUSA) jumped 137.4% to $4.5150 amid continued momentum and an increase in the price of oil. Imperial Petroleum Inc. (NASDAQ:... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! Let's get right into it with an overview of the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
A Peek Into The Markets: US Stock Futures Tumble; Crude Oil Jumps Over 7%
Pre-open movers U.S. stock futures traded lower in early pre-market trade amid escalating Russia-Ukraine concerns. Investors are awaiting earnings results from Ciena Corporation... 
Via Benzinga
5 Stocks To Watch - Monday, Mar. 7
Some of the stocks that may grab investor focus today. 
Via Talk Markets
5 Stocks To Watch For March 7, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects Ciena Corporation (NYSE: CIEN) to report quarterly earnings at $0.45 per share on revenue of $856... 
Via Benzinga
FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies
The FDA has extended the review period for Bluebird bio Inc's (NASDAQ: BLUE) biologics licensing applications (BLA) for its lentiviral vector gene... 
Via Benzinga
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company... 
Via Benzinga
Bluebird bio Lays Out Planned Updates Ahead Of J.P. Morgan Healthcare Conference
Bluebird bio Inc (NASDAQ: BLUE) announced planned updates to be presented at the 40th Annual J.P. Morgan Healthcare conference, including 2022 program milestones and... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.